Understanding the Difference Between a Technology Owner and a Reseller/Customizer
National pharmaceutical traceability systems play a critical role in protecting patients, ensuring pharmaceutical supply chain transparency, and supporting regulatory compliance with global regulatory requirements. Because these systems become long-term digital infrastructures, the choice of technology partner is one of the most important decisions in the development of a national track & trace program, particularly when establishing a national pharmaceutical traceability system (Designing National Traceability Systems: The Pharma Case).
Governments and regulatory authorities generally face two different approaches: working directly with the technology owner that develops and controls the solution or relying on a reseller/customizer that implements and adapts a platform provided by another vendor. This distinction is particularly important for national-scale track & trace infrastructure, where technology ownership, accountability, and long-term system management can directly affect program performance.
To understand the strategic implications of this choice, it is important to clearly define the difference between these two roles:
- A technology owneris the company that develops and owns the core traceability solution. It controls the source code, manages the product roadmap, and is responsible for the continuous evolution, maintenance, and improvement of the platform. By maintaining direct technology ownership, the provider can ensure faster adaptation to new regulatory requirements, security needs, interoperability standards, and future system developments.
- A reseller/customizeris a local or regional company that distributes, implements, or configures a solution originally developed by another technology provider. While it may offer valuable implementation support, integration capabilities, or local expertise, it does not control the underlying technology and depends on the original owner for major updates, product evolution, and strategic changes.
Although both models exist in the market, the distinction becomes particularly relevant in national-scale programs. A pharmaceutical traceability system must remain reliable, secure, and adaptable over many years. For this reason, establishing a direct relationship with the technology owner provides greater accountability, stronger control over the system lifecycle, and a more sustainable foundation for long-term regulatory compliance and national track & trace continuity.
The Risks of Relying on Resellers in National Track & Trace Programs
In national pharmaceutical track & trace programs, clear ownership and responsibility are essential. When a reseller acts as an intermediary between the regulator and the technology provider, accountability can become fragmented, potentially creating additional layers in technology governance and system management.
In the event of technical issues, such as software bugs, security vulnerabilities, or system updates, the reseller may need to coordinate with the original technology owner before a solution can be delivered. This additional layer can create delays, particularly when rapid responses are required to maintain regulatory compliance, system availability, and the operational continuity of national pharmaceutical traceability infrastructure.
Reduced Control Over Technology Evolution and Roadmap Priorities
A national traceability system must continuously evolve to address new regulatory requirements, security standards, interoperability frameworks, and operational needs. However, resellers typically do not control the development product roadmap of the underlying platform.
If authorities require new functionalities, urgent compliance updates, or changes to the core solution, the reseller can only submit requests to the technology owner (Pharmaceutical Traceability Systems: Risks of Unproven Providers & Best Practices) without having direct control over development priorities, timelines, or implementation decisions. This can limit the regulator’s direct influence over technology evolution, platform development, and future track & trace system capabilities.
Additional Complexity in Technical Support and System Management
Large-scale pharmaceutical traceability platforms involve complex integrations and high transaction volumes. Issues related to EPCIS (DSCSA Compliance in Practice: Building Interoperable Traceability Workflows) data exchange, system interoperability, validation processes, data integration, or performance management require direct access to deep technical expertise.
When communication must pass through an intermediary, troubleshooting processes may become more complex, potentially increasing resolution times for critical operational challenges. Direct access to the technology provider, technical teams, and platform developers can instead support faster issue resolution, system maintenance, and technical support.
Long-Term Continuity Risks for National Infrastructure
National traceability systems are designed to operate for decades, requiring stable governance, continuous innovation, reliable technological support, and effective lifecycle management.
Depending heavily on a reseller can introduce long-term risks if the commercial relationship changes, the reseller exits the market, or strategic priorities shift. Working directly with the technology owner helps ensure continuity, direct access to expertise, and a stronger foundation for the future evolution of the program. This direct technology partnership can also reduce vendor dependency and strengthen the long-term sustainability of critical national digital infrastructure.
The Strategic Advantages of Working Directly with the Technology Owner in National Track & Trace Programs
Working directly with the technology owner provides regulators and program stakeholders with direct access to the teams that designed, developed, and maintained the traceability platform.
This direct connection enables faster identification and resolution of technical challenges, ensuring that system updates, regulatory changes, and operational requirements are implemented accurately and efficiently. For complex infrastructures such as national pharmaceutical track & trace systems, access to specialized technical expertise is essential to maintain reliability, performance, scalability, and performance over time.
Direct access to the original technology provider also strengthens technology governance, improves communication, and provides greater visibility into the platform’s development and long-term technology roadmap.
Clear Accountability for Security, Compliance, and System Performance
In a national traceability program, responsibility must remain clearly defined. A direct relationship with the technology owner eliminates additional layers between the organization managing the system and the team responsible for the underlying technology.
The technology owner remains directly accountable for critical aspects such as system availability, cybersecurity, maintenance, software updates, technical performance, and compliance with applicable requirements. This clear ownership model strengthens governance and reduces potential coordination challenges across the national track & trace infrastructure.
Faster Innovation and Adaptation to Regulatory Evolution
Pharmaceutical traceability requirements continue to evolve as global standards, interoperability frameworks, and industry expectations develop. National track & trace systems therefore require continuous technological evolution rather than one-time implementation.
Technology owners manage their own product roadmap, allowing them to continuously improve the platform and adapt to emerging requirements, including updates from organizations such as GS1 (Regulatory Traceability in Pharma | Compliance Challenges & Best Practices) and evolving international traceability frameworks. Direct collaboration enables regulators to benefit from ongoing innovation rather than depending on third-party prioritization.
This approach can facilitate faster regulatory updates, interoperability improvements, security enhancements, and new functionality while supporting the long-term evolution of the pharmaceutical traceability platform.
Long-Term Sustainability and Program Continuity
National track & trace infrastructures are designed to operate over the long term and require continuous investment, maintenance, technological evolution, and lifecycle management.
Technology owners typically invest in ongoing development, certifications, security improvements, and deployments across different markets. Partnering directly with the company responsible for the core solution provides greater confidence in the continuity, scalability, and future readiness of the system throughout its lifecycle.
For governments and regulatory authorities, this direct relationship can support long-term system sustainability, continuous technical support, and the ability to adapt the national traceability infrastructure as regulatory and operational requirements evolve.
Building Sustainable National Track & Trace Systems Through Direct Technology Ownership
National pharmaceutical track & trace systems (Pharma Track & Trace Systems for Compliance and Safety) require more than an initial implementation: they need long-term reliability, continuous development, and clear governance to support evolving regulatory and operational needs. As critical digital infrastructure, these systems must be designed for scalability, security, interoperability, and long-term operational continuity.
While resellers can provide valuable local expertise, implementation support, system integration, and market knowledge, relying on an intermediary may introduce additional complexity in areas such as accountability, technology evolution, and long-term system management.
By establishing a direct relationship with the technology owner, governments and regulatory authorities gain access to the teams responsible for the core solution, a clearer governance model, and a stronger foundation for ongoing compliance, innovation, and system continuity. Direct access to the original technology provider can also strengthen traceability governance, improve technical communication, and reduce dependency on third-party technology decisions.
For critical national health infrastructures, choosing a technology partner with direct technology ownership and long-term commitment can play a decisive role in ensuring that the national traceability system remains secure, scalable, and effective throughout its lifecycle.
Ultimately, direct collaboration with the technology owner provides a stronger foundation for sustainable pharmaceutical track & trace programs (Pharmaceutical Serialization and Traceability for Health Security), continuous innovation, and future-ready national traceability infrastructure.
Coming soon: From Tax Stamps to Illicit Vapes: How Criminal Networks Adapt as Tobacco Markets Change
